GSEP
COGT icon

Golden State Equity Partners’s Cogent Biosciences COGT Stock Holding History

Golden State Equity Partners’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.62K Buy
+120
New +$4.43K ﹤0.01% 1489

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Golden State Equity Partners's COGT Position: Q1 2026 in Review

Golden State Equity Partners opened a new position in Cogent Biosciences (COGT) in Q1 2026: 120 shares worth $4.62K. The stake represents ﹤0.01% of the portfolio and ranks #1489 among its holdings.

305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Golden State Equity Partners held 120 shares of Cogent Biosciences worth $4.62K as of Q1 2026.
  • Cogent Biosciences was a new Golden State Equity Partners position in Q1 2026.
  • Cogent Biosciences made up ﹤0.01% of Golden State Equity Partners's portfolio in Q1 2026, its #1489 holding.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Golden State Equity Partners's 13F filing for Q1 2026, filed 28 Apr 2026.